Virtual screening and molecular docking of flavonoid compounds as BACE-1 inhibitors for Alzheimer's Disease: identification of Betagarin as a promising nutraceutical lead candidate.
Alzheimer's Disease (AD) is a progressive neurodegenerative disorder accounting for 60-70% of dementia cases globally, with the β-site amyloid precursor protein cleaving enzyme-1 (BACE-1) representing one of the most intensively studied therapeutic targets due to its rate-limiting role in amyloid-β (Aβ) peptide product...